Mucormycosis infection in patients with COVID-19: A systematic review.

Seyed Ahmad Seyed AlinaghiAmirali KarimiAlireza BarzegaryZahra PashaeiAmir Masoud AfsahiSanam AlilouNazanin JanfazaAlireza ShojaeiFatemeh AfroughiParsa MohammadiYasna SoleimaniNewsha NazarianAva AmiriMarcarious M TantuoyirShahram OliaeiSeyed Ahmad Seyed Alinaghi Omid Dadras

Published in: Health science reports (2022)

Early diagnosis of mucormycosis co-infection in COVID-19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co-morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co-infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
primary care
patient reported outcomes
physical activity